
ASRT Stock Forecast & Price Target
ASRT Analyst Ratings
Bulls say
Assertio Hldgs is poised for success due to the increased offer and fully-committed financing commitments from Garda Therapeutics, representing a premium to the original offer and a significant increase from Assertio's pre-offer stock price. The company's Board of Directors has determined that this offer provides the most favorable outcome for stockholders, leading to a Buy rating and a raised price target of $21.80 per share. The successful completion of the transaction is expected to further boost the company's financials and remove its common stock from public trading.
Bears say
Assertio Hldgs is projected to face significant challenges in the near future due to a sharp decrease in service revenue and other income, as well as a significant loss on impairment of intangible assets. These factors will likely lead to a decrease in profitability and threaten the company's ability to meet its financial obligations and fund future growth initiatives. The recent reverse stock split may provide temporary relief, but given the heightened risks and uncertainties faced by the company, we maintain our negative outlook on its stock.
This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ASRT Analyst Forecast & Price Prediction
Start investing in ASRT
Order type
Buy in
Order amount
Est. shares
0 shares